Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An announcement from Alliance Pharma ( (GB:APH) ) is now available.
Alliance Pharma reported its preliminary results for the year ended December 31, 2024, with performance aligning with expectations. The company experienced a 1% decline in revenue compared to the previous year, but saw a 4% increase in gross profit and a 37% rise in free cash flow. Structural changes and new senior management hires have positioned the company for medium-term growth. The company also made significant strides in reducing emissions and successfully appealed a Competition and Markets Authority decision. Additionally, Alliance Pharma announced its acquisition by Aegros Bidco Ltd, with plans to cease trading on AIM by mid-2025.
More about Alliance Pharma
Alliance Pharma plc is a growing consumer healthcare company headquartered in the UK. The company focuses on empowering people to improve their health and wellbeing by providing trusted and proven brands globally. Alliance Pharma invests in priority brands, innovation, and selective geographic expansion, while maintaining an asset-light model by outsourcing manufacturing and logistics.
YTD Price Performance: 40.11%
Average Trading Volume: 6,543,695
Technical Sentiment Signal: Strong Sell
Current Market Cap: £347M
See more insights into APH stock on TipRanks’ Stock Analysis page.